Group 1 - The core focus of WuXi AppTec is on its GLP-1 drug pipeline, with the company currently supporting 24 GLP-1 drugs, including both small molecules and peptides [1][2] - Out of the 24 GLP-1 drugs, 15 have entered phase II and III clinical trials, positioning the company to potentially capture approximately 25% of the global GLP-1 market share [1] Group 2 - The demand for GLP-1 drugs has seen exponential growth, revealing deficiencies in the core pharmaceutical supply chain, which has been historically rare [2] - WuXi AppTec has proactively built its production capacity, recently completing the construction of a 100,000-liter solid-phase synthesis reactor to enhance large-scale production capabilities [2] - As the accessibility of GLP-1 drugs improves, the treatment landscape for obesity and related metabolic diseases is expected to undergo significant transformation, indicating the beginning of a "therapeutic revolution" [2]

Core Insights - WuXi AppTec (603259.SH, 02359) presented at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, updating on its business progress [2] - As of Q3 2025, the company has a total of 3,430 small molecule CDMO pipelines, representing 16% of the global clinical-stage new drug pipelines, with 167 projects in Phase III and commercialization [2] - The number of Phase III and commercial projects has increased from 107 in 2022 to 167, marking a growth of 56%, with corresponding revenue rising from 4.7 billion to 10.3 billion yuan, and expected to reach a new high this year [2] Industry Trends - Oral medications are rapidly replacing injectables in mainstream treatment areas due to their convenience, becoming a new focus in the pharmaceutical industry [2] - Recently, industry media Endpoints News identified "Pills" as a key term for 2025, highlighting the strong rise of this sector [2] - Oral formulations are expanding in areas such as obesity, heart disease, and inflammatory diseases, continuously capturing market share previously dominated by large molecule biologics [2]

Core Insights - WuXi AppTec (603259.SH, 02359) presented at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, updating on its business progress [1] - As of Q3 2025, the company has a total of 3,430 small molecule CDMO pipelines, representing 16% of the global clinical-stage new drug pipelines, with 167 projects in Phase III and commercialization [1] - The number of Phase III and commercial projects has increased from 107 in 2022 to 167, marking a growth of 56%, with corresponding revenue rising from 4.7 billion yuan to an expected 10.3 billion yuan in 2024, potentially reaching a new high this year [1] Industry Trends - Oral medications are rapidly replacing injectables in mainstream treatment areas due to their convenience, becoming a new focus in the pharmaceutical industry [1] - Industry media, Endpoints News, has identified "Pills" as a key term for 2025, indicating the strong rise of this sector, with oral formulations expanding in areas such as obesity, heart disease, and inflammatory diseases, capturing market share previously dominated by large molecule biologics [1]

来源：格隆汇APP 利润端表现尤为突出，增长幅度显著高于营收：归母净利润预计约191.51亿元，同比大幅增长 102.65%；经调整non-IFRS归母净利润约149.57亿元，同比增长41.33%；扣非后归母净利润约132.41亿 元，同比增长32.56%。 据此预增数据，药明康德2025年在营收及上述三项利润指标上均创历史新高。 根据其公布的演示材料，药明康德的小分子原料药合成反应釜已在2025年底达到400万升。这意味着， 经过二十五年在全球范围内的能力与规模积累，公司已建立起强劲的商业化供应体系。 此外，数据显示，截至去年第三季度，药明康德小分子CDMO管线总数已达3430个，其中商业化分子数 量首次增至80个，占全球临床阶段小分子新药比例的16%。 本周早些时候，药明康德发布2025年度业绩预增公告。公司预计全年实现营业收入约454.56亿元，同比 增长15.84%；其中持续经营业务收入同比增长21.4%，显示主营业务增长强劲。 2026年1月14日，药明康德(603259.SH/2359.HK)在第44届JPM医疗健康大会上发表主题演讲，并更新了 公司业务进展。 ...

Core Insights - WuXi AppTec (603259.SH/2359.HK) presented at the 44th JPM Healthcare Conference, updating on its business progress [1] Group 1: Business Development - The company’s small molecule API synthesis capacity reached 4 million liters by the end of 2025, indicating a robust commercial supply system built over 25 years [1] - As of Q3 last year, WuXi AppTec's small molecule CDMO pipeline totaled 3,430, with 80 commercial molecules, representing 16% of the global clinical stage small molecule new drugs [1] Group 2: Financial Performance - WuXi AppTec expects a revenue of approximately 45.456 billion yuan for the full year 2025, reflecting a year-on-year growth of 15.84%, with a 21.4% increase in revenue from continuing operations [1] - The company anticipates a significant profit increase, with net profit attributable to shareholders expected to be around 19.151 billion yuan, a substantial year-on-year growth of 102.65% [1] - Adjusted non-IFRS net profit is projected at approximately 14.957 billion yuan, a year-on-year increase of 41.33%, while the net profit after deducting non-recurring items is expected to be about 13.241 billion yuan, up 32.56% year-on-year [1] - The pre-announcement data indicates that WuXi AppTec will achieve historical highs in revenue and the three profit metrics for 2025 [1]

Core Insights - WuXi AppTec (603259.SH/2359.HK) presented at the 44th JPM Healthcare Conference, updating on its business progress [1] Business Development - The company’s small molecule API synthesis capacity reached 4 million liters by the end of 2025, indicating a robust commercial supply system built over 25 years [1] - As of Q3 last year, WuXi AppTec's small molecule CDMO pipeline totaled 3,430, with 80 commercial molecules, representing 16% of the global clinical stage small molecule new drugs [1] Financial Performance - WuXi AppTec expects a revenue of approximately 45.456 billion yuan for the full year 2025, a year-on-year increase of 15.84%, with a 21.4% growth in continuing operations revenue [1] - The profit performance is particularly strong, with a projected net profit attributable to shareholders of about 19.151 billion yuan, a significant year-on-year increase of 102.65% [1] - Adjusted non-IFRS net profit is expected to be around 14.957 billion yuan, up 41.33% year-on-year, while the net profit after deducting non-recurring items is projected at approximately 13.241 billion yuan, a 32.56% increase year-on-year [1] - The pre-announcement data indicates that WuXi AppTec will achieve historical highs in revenue and the three profit metrics for 2025 [1]

利润端表现尤为突出，多项指标呈现高速增长：经调整non-IFRS归母净利润约149.57亿元，同比增长 41.33%；归母净利润约191.51亿元，同比大幅增长102.65%；扣非后归母净利润约132.41亿元，同比增 长32.56%。 据此次披露，药明康德2025年在营收及上述三大利润指标上均创下历史新高，展现出整体经营的强劲态 势与盈利质量的持续提升。 就在本周早些时候，药明康德发布了2025年度业绩预增公告。公告显示，公司全年预计实现营业收入约 454.56亿元，同比增长15.84%；其中持续经营业务收入同比增长21.4%，增长势头稳健。 2026年1月14日，药明康德(603259.SH/2359.HK)在第44届摩根大通医疗健康大会上发表主题演讲，根据 公司所披露的财务数据显示，公司2025年经调整non-IFRS利润率近33%，创历史新高。 ...

药明康德 ：将以每股1元人民币的价格配售5840万股新H股。 ...

药明康德：将以每股1元人民币的价格配售5840万股新H股。 ...

PresentationGood morning, everyone. I'm Yang Huang, China Healthcare analyst of JPMorgan based in Hong Kong. Welcome to the third day of our JPMorgan Healthcare Conference. This morning's session is going to be kicked off by WuXi AppTec, and we have WuXi AppTec Co-CEO, Dr. Minzhang Chen, who is going to give us a presentation. Dr. Chen?Minzhang ChenCo-CEO & Executive Director All right. Thank you, Yang. Good morning, everyone. Happy New Year. I'm glad to be here first today to kick off the day. I hope our p ...